TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
40.06
+0.76 (1.93%)
At close: Jun 6, 2025, 4:00 PM
40.00
-0.06 (-0.15%)
After-hours: Jun 6, 2025, 6:43 PM EDT
TG Therapeutics Revenue
TG Therapeutics had revenue of $120.86M in the quarter ending March 31, 2025, with 90.40% growth. This brings the company's revenue in the last twelve months to $386.39M, up 33.54% year-over-year. In the year 2024, TG Therapeutics had annual revenue of $329.00M with 40.80% growth.
Revenue (ttm)
$386.39M
Revenue Growth
+33.54%
P/S Ratio
14.79
Revenue / Employee
$1,143,154
Employees
338
Market Cap
5.84B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
Dec 31, 2020 | 152.00K | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TGTX News
- 11 hours ago - TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 9 days ago - TG Therapeutics: Estimates Could Soon Be Raised Again - Seeking Alpha
- 10 days ago - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting - GlobeNewsWire
- 4 weeks ago - TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show - Benzinga
- 4 weeks ago - TG Therapeutics: Share Price Slip On Q1 Earnings Unsurprising Given Challenges - Seeking Alpha
- 4 weeks ago - TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance - GlobeNewsWire
- 5 weeks ago - TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update - GlobeNewsWire